FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Peptide Library

Tesamorelin

Egrifta / TH9507

Growth Hormone Secretagogues

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

Mechanism of Action

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

Research Protocols

For research purposes only. Not medical advice.

FDA-approved protocol: 2mg daily via subcutaneous injection. Research protocols follow the same dosing. Administered at a consistent time daily, typically in the morning.

Research Notes

Clinical Research Status

Tesamorelin received FDA approval in November 2010 for the treatment of HIV-associated lipodystrophy and is marketed by Theratechnologies as Egrifta and Egrifta SV (single-vial formulation). Multiple Phase III clinical trials (including the landmark studies with over 800 HIV patients) demonstrated statistically significant visceral adipose tissue reduction of approximately 15-18% over 26 weeks. Ongoing research explores applications in non-alcoholic fatty liver disease (NAFLD), cognitive decline in aging and HIV, and broader metabolic syndrome indications beyond the HIV population.

Key Published Findings

Pivotal trials demonstrated that tesamorelin 2mg daily subcutaneous injection reduced visceral adipose tissue by a mean of 15.2% versus placebo over 26 weeks, with continued maintenance of reduction over 52 weeks of treatment. A landmark study published in Neurology showed tesamorelin improved cognitive function in older adults with mild cognitive impairment or subjective cognitive complaints, suggesting neuroprotective properties mediated through GH/IGF-1 signaling. Research has also demonstrated improvements in liver fat content and NAFLD biomarkers, with hepatic fat reduction of approximately 35% in HIV patients with fatty liver.

Safety Profile

Tesamorelin is generally well-tolerated with the most common adverse effects being injection site reactions (erythema, pruritus, pain) reported in approximately 8-13% of clinical trial participants. Fluid retention, arthralgia, and paresthesias occur at rates slightly above placebo, consistent with physiological GH elevation. The compound is contraindicated in pregnancy, patients with active malignancy, and those with disruption of the hypothalamic-pituitary axis, and carries warnings regarding potential glucose intolerance.

Drug Interactions & Contraindications

Tesamorelin may reduce the efficacy of cortisol replacement therapy by increasing cortisol-binding globulin, and patients on glucocorticoid replacement should be monitored. It should be used cautiously with drugs affecting glucose metabolism (insulin, oral hypoglycemics) as GH elevation can impair insulin sensitivity. The compound is contraindicated in patients with active malignancy due to the proliferative effects of elevated GH/IGF-1, and patients with a history of hypothalamic-pituitary tumors should not use it.

Comparison to Related Compounds

Unlike synthetic GH (somatropin) which provides a constant supraphysiological GH level, tesamorelin preserves the natural pulsatile pattern of GH release and maintains hypothalamic-pituitary feedback, resulting in a more physiological GH profile. Compared to CJC-1295 (a modified GHRH analog popular in peptide research), tesamorelin has the advantage of FDA approval, extensive clinical trial data, and insurance coverage for qualifying HIV patients. Sermorelin is a shorter GHRH fragment (1-29) with similar mechanism but lower potency and shorter half-life, requiring more frequent dosing.

Community Observations

Practitioners and patients report that the visceral fat reduction becomes measurable on DEXA scans within 3-4 months, with peak effects at 6-9 months of consistent daily use. The research and TRT community has adopted tesamorelin for its GH-elevating effects beyond the HIV population, noting improvements in sleep quality, body composition, and skin quality. Users frequently note that results reverse within 3-6 months of discontinuation, indicating the need for ongoing treatment, and many physicians prescribe it alongside testosterone replacement therapy for synergistic metabolic benefits.

Half Life

~26-38 minutes

Reconstitution

Sterile water (provided with kit)

Storage

Lyophilized

Refrigerate 2-8C. Protect from light.

Reconstituted

Use immediately after reconstitution. Discard unused portion.

US Legal Status

FDA-approved (Rx only)

Also Known As

EgriftaTH9507

Frequently Asked Questions

What is Tesamorelin?

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

How does Tesamorelin work?

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

What is the US regulatory status of Tesamorelin?

FDA-approved (Rx only)

What is the half-life of Tesamorelin?

~26-38 minutes

What else is Tesamorelin called?

Egrifta, TH9507

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer